| Previous close | 32.40 |
| Open | 32.40 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 810.00 |
| Expiry date | 2025-01-17 |
| Day's range | 32.40 - 32.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 80 |
Investor's Business DailyRegeneron Earnings Miss; Biotech Giant's Stock Falls
Regeneron Pharmaceuticals earnings and sales missed first-quarter estimates early Thursday. Shares fell slightly.
- Reuters
UPDATE 2-Regeneron misses profit estimates on weaker Eylea and Dupixent sales
U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday, due to softer sales of its blockbuster eye drug Eylea and its eczema treatment Dupixent. The company reported an adjusted profit of $9.55 per share for the quarter, compared with analysts' estimates of $10.09, according to LSEG data. Regeneron has been looking to switch Eylea patients to the high-dose version as the eye drug, which has long been its cash cow, faces the threat of biosimilars and fierce competition from rivals including Roche's Vabysmo.
GlobeNewswireRegeneron Reports First Quarter 2024 Financial and Operating Results
First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP dil
